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KEY POINTS
 The pathology of Parkinson’s disease (PD) extends far beyond the nigrostriatal dopamine
pathway and results in nonmotor symptoms (NMS) in addition to the commonly accepted
motor symptoms.
 NMS have a great impact on quality of life, but nonrecognition of NMS is an all too com-
mon problem, requiring a systematic approach to both recognizing and treating NMS.
 There are many useful questionnaires that might be used to detect and guide manage-
ment of NMS.
 The number of evidence-based treatments for these problems remains limited.
 More work needs to be done in therapeutics, and it seems that future therapies for NMS
should be developed specifically based on the pathogenesis of PD.
 Therapeutic strategies that use serotonin-based and noradrenaline-based approaches, in
addition to dopamine therapy, may provide a more comprehensive control of the multi-
tude of symptoms seen in most patients with PD.INTRODUCTION
Ever since it was first recognized,1 Parkinson’s disease (PD) has been primarily iden-
tified by its cardinal motor symptoms: tremor, bradykinesia, muscle rigidity, and gait
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Sung & NicholasS2goal of improving motor symptoms and preserving independent function by
enhancing dopamine tone.2 However, intrinsic nonmotor symptoms (NMS) of PD
are increasingly recognized as being critical to identify and treat because of their
impact on quality of life in PD,4–11 perhaps having an even greater impact than motor
symptoms.12 Despite increasing evidence of the importance of NMS on quality of life,
studies clearly show that there are gaps in treatment of these issues.11 Although phy-
sicians may be aware that NMS are common in PD, these gaps in treatment may be
attributable to a need for increased information about and understanding of specific
NMS, and clinical approaches for their assessment and management in the context
of PD as a whole. This article discusses NMS of PD, how they may be related to the
pathologic basis of PD, and how NMS can be best managed.OVERVIEW OF NMS
The most commonly described primary NMS of PD (summarized in Table 1) are auto-
nomic dysfunction, cognitive abnormalities, sleep disorders, mood disorders, pain,
and sensory disorders.7,9,10,13 These NMS are common in patients with PD, with the
most common being autonomic dysfunction, mood disorders, and sleep prob-
lems.13–15 There are also NMS in PD that are secondary to pharmacotherapy treat-
ment, such as impulse control disorders and psychosis. In addition to being
common, NMS have been reported by patient surveys to be more disabling than
the motor symptoms of tremor and bradykinesia.5
Autonomic Dysfunction
Autonomic dysfunction associated with PD primarily consists of gastrointestinal (GI)
dysfunction, genitourinary dysfunction, and cardiovascular dysfunction with ortho-
static hypotension. Although it is a key feature of multiple system atrophy, autonomic
dysfunction also commonly occurs in PD and is considered to be the most prevalent
category of NMS, affecting more than 70% of patients in all stages of PD.16
Dysautonomia manifested as GI dysfunction, particularly constipation, is one of the
most common NMS, with prevalence in the 50% to 70% range.16,17 GI dysfunction
was even described in James Parkinson’s original monograph on PD1 and often pre-
cedes the development of motor symptoms.17 Another GI symptom includes drooling/
sialorrhea, which is believed to be as much caused by decreased involuntary swallow-
ing as it is to increased saliva production, and is believed to have a prevalence greater
than 40%.17 Incomplete bowel evacuation and bowel incontinence may also occur,
but these are less common (30% and 8%, respectively) than constipation or drool-
ing/sialorrhea.17
Genitourinary dysfunction is a frequent manifestation of dysautonomia in PD, mostly
consisting of urinary urgency, frequency, and incontinence, and includes sexual
dysfunction. Urinary dysfunction can be objectively assessed with urodynamic studies
and is estimated to have a prevalence of 25% to 40%.17–19 Sexual dysfunction in men
with PD manifests primarily as erectile dysfunction; however, decreases in drive and
orgasm have also been reported.20
One of the most debilitating NMS is the subcategory of dysautonomia categorized
as cardiovascular dysfunction. Cardiac sympathetic denervation is known to occur in
PD and is at least partially responsible for contributing to an array of symptoms
ranging from orthostatic lightheadedness and hypotension to dyspnea on exertion
and fatigue.21 Although generally occurring later in the disease course and less severe
than in multiple system atrophy, orthostatic hypotension can be particularly problem-
atic, resulting in cerebral hypoperfusion, which may impair cognition. When severe,
Table 1
NMS of PD
Category Subcategory Examples
Autonomic dysfunction Gastrointestinal dysfunction Constipation
Sialorrhea/drooling
Fecal incontinence
Genitourinary dysfunction Urinary urgency/frequency
Urinary incontinence
Sexual dysfunction
Cardiovascular dysfunction Orthostatic lightheadedness/
hypotension
Dyspnea on exertion
Fatigue
Cognitive dysfunction Bradyphrenia
Executive dysfunction
PD dementia
Sleep disorders REM sleep behavior disorder
Restless legs syndrome
Periodic limb movements of
sleep
Excessive daytime somnolence
Insomnia
Mood disorders Depression
Anxiety/panic attacks
Pain and sensory disorders Pain Paresthesias
Limb pain
Joint pain
Visceral pain
Olfactory dysfunction Loss of sense of smell
NMS secondary to
pharmacotherapy
Impulse control disorders Obsessive-compulsive
behaviors
Psychosis Visual hallucinations
Delusions
Illusions
Abbreviation: REM, rapid eye movement.
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1100 patients with PD, the prevalence of symptomatic orthostatic hypotension was
18%,22 whereas in another study, it was as high as 32%.17 Compounding this problem
is that pharmacotherapy with levodopa or the dopamine agonists is known to worsen
orthostatic hypotension, wherein the patient symptoms are dually caused by the PD
process itself and by treatment of motor symptoms. Although fatigue in patients
with PD is common, with prevalence of fatigue ranging from 33% to 58%, and has
multiple contributors and is poorly understood, autonomic dysfunction may play a
role in its occurrence.10,13,23
Cognitive Dysfunction
Cognitive dysfunction in PD may present in varying degrees. Occurrence is common
even among patients with mild PD, and includes difficulties such as bradyphrenia, or
slowing of thinking, and executive dysfunction, such as impairment of planning and
goal-directed behaviors.24 When cognitive dysfunction reaches a level of impairment
in activities of daily living, it is classified as PD dementia, with its prevalence in the 20%
Sung & NicholasS4to 44% range.17,21 Although the impairments on neuropsychological testing are similar
between PD dementia and dementia with Lewy bodies, the dementia in PD, if it oc-
curs, appears years after the onset of motor symptoms. In contrast to dementia
seen in Alzheimer disease, PD dementia has relative sparing of encoding of short-
term memories, and other cortical features such as aphasia and apraxia are usually
absent.
Sleep Disorders
Sleep disorders associated with PD include rapid eye movement (REM) sleep behavior
disorder, restless legs syndrome, periodic limb movements of sleep, insomnia, and
excessive daytime somnolence (EDS).25 In a study by Tandberg and colleagues,26
two-thirds of all patients with PD reported a sleep disorder, and an international
study17 found that 37% of patients reported a sleep disorder. In milder forms, prob-
lems may be restricted to fragmentation of nocturnal sleep. However, when combined
with restless legs syndrome and periodic limb movements of sleep, these problems
can be compounded and lead to insomnia and subsequent EDS. Similar to constipa-
tion, REM sleep behavior disorder often precedes the motor onset of the disease and
has been evaluated as a predictor for the development of PD.27–29 Sleep behavior dis-
order is characterized by recurrent dream enactment behavior during characteristic
REM sleep, but without atonia on polysomnography.27 Although the effect of sleep
behavior disorder may be greater on the patient’s bedmate than on the patients
with PD, perhaps the greatest importance of sleep behavior disorder is early recogni-
tion and surveillance for the onset of PD.
Mood Disorders
Mood disorders in PD consist primarily of depression and anxiety, but can also include
psychosis and apathy.30 Anxiety disorders, including generalized anxiety disorder,
agoraphobia, panic disorder, and social phobia, have all been reported in PD, with
a prevalence of 20% to 40%.6,17,31 The prevalence of depression in PD is estimated
to be 40%, although only a few (4%–6%) meet the Diagnostic and Statistical Manual
of Mental Disorders, Fourth Edition criteria for major depression.21 In contrast to pri-
mary depression, patients with PD show more dysphoria and irritability, but less guilt
and a lower incidence of suicide.32 As a result, the depression in PD is believed to be
related more to primary neuropathology selective to the disease state, rather than a
secondary reaction to motor deficits in PD.21,32
NMS Secondary to Pharmacotherapy
As mentioned earlier, certain NMS may occur as a result of pharmacotherapy for PD.
Impulse control disorders are complex behavioral problems and may include patho-
logic gambling, hypersexuality, compulsive shopping, and compulsive eating. With
a reported prevalence up to 13.6%, these impulse control disorders occur more
frequently in patients with PD than in the general population, and are critical to recog-
nize because of the known link to treatment, especially dopamine agonists.33
In addition, vivid dreams and frank psychosis may occur as a result of dopamine-
replacement therapy. Psychosis may occur in up to one-third of all patients with
PD.17,21,34 Themost commonly described psychotic symptoms are hallucinations, de-
lusions, and illusions. Hallucinations are usually nonthreatening and visual, as
opposed to the auditory hallucinations more frequently seen in primary psychiatric dis-
orders. The most commonly described visual hallucinations include seeing crawling
bugs, as well as small animals or people (Lilliputian figures), including children.34 In
a medical illness setting, psychosis such as from dehydration or infection may also
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in any patient with PD who develops acute psychosis in the absence of changes to
dopamine therapy.
Because PD is primarily regarded as a movement disorder, the natural focus on mo-
tor symptoms often leads to underrecognition of NMS by patients and clinicians.23,35
The importance of recognizing NMS in PD is highlighted by the expanding evidence
that NMS cause significant morbidity for patients with PD, perhaps equal to the
morbidity caused by the motor symptoms themselves, and this is particularly true in
patients with advanced disease.6,23 In addition, the wearing-off phenomenon most
often accompanying motor symptoms has also been described with NMS for more
than 20 years and continues to be difficult to identify and treat.36,37PATHOPHYSIOLOGY OF PD MOTOR SYMPTOMS AND NMS
Although the precise pathophysiology of most NMS is not known, the traditional view-
point that PD is caused by a pure dopamine deficiency beginning in the substantia
nigra (SN) is insufficient to explain the asis of NMS. The pathology of PD reflects ab-
normalities in multiple neurotransmitters, from the cortex to the brainstem and even
outside the central nervous system (CNS) altogether. Historically, PD has been linked
to depigmentation of the midbrain SN, with surviving neurons in this nucleus contain-
ing cytoplasmic inclusions called Lewy bodies.38,39 These cells were known for
providing dopamine to the striatum, and when this catecholamine was measured in
patients with PD who had never been treated, it was decreased by approximately
90% in that area of the brain.40 As a result, most of the pharmacologic therapies for
PD have focused on replenishing the CNS dopamine deficiency in these patients,3
with generally good recovery of motor deficits.2
However, the hypothesis that PD is primarily a dopamine deficiency in the brain
caused by degeneration of the nigrostriatal pathway was seriously challenged when
Braak and Braak41 introduced their pathologic staging system, which denoted stage
1with initial degeneration in the caudal brainstem or olfactory bulbs. This degeneration
manifests clinically as the NMS of olfactory loss that has been implicated in the preclin-
ical stages of PD.28Although not accounted for in theBraak staging system, thePDpre-
motor symptomof GI dysfunctionmay be explained by the discovery that Lewy bodies,
also immunoreactive for a synuclein, were increased in the myenteric plexus of the GI
tract in patients with PD.42–44 This finding has been applied to suggest that the pathol-
ogy of PD extends beyond the brain and may even preclude CNS involvement.43
Braak stage 2 involves progression of neurodegeneration to the lower brainstem,
where key nondopamine nuclei are found. For example, noradrenaline (NA)-producing
cells in the locus coeruleus (LC) of the dorsal pons45,46 and in the reticular formation of
the medulla oblongata46,47 have long been shown to be degenerated in patients with
PD. These nuclei play an important role in central autonomic control and are thus
implicated in the pathogenesis of the NMS of autonomic dysfunction.4,48,49 Also
potentially degenerated at this stage are the raphe nuclei, which produce serotonin
(5-HT). This observation is supported by the findings that 5-HT levels in the brains
of patients with PD have been shown to be decreased by 56% in the striatum50 and
by 50% in the frontal cortex of nontreated patients.45 As a result, the degeneration
of these NA and 5-HT systems has been implicated in the cause of the mood symp-
toms of PD.30
Braak stages 3 and 4 describe progression of degeneration to the midbrain, espe-
cially to the SN, where loss of dopamine cells has long been linked to the cardinal mo-
tor symptoms of tremor, rigidity, and bradykinesia.40 It is at this stage that PD crosses
Sung & NicholasS6from a premotor disorder to a motor disorder and is usually clinically diagnosed. How-
ever, there are also some implications that dopamine loss influences NMS as well. For
example, the role of dopamine in sleep disorders of patients with PD has been sug-
gested because of its function as a modulator of the sleep-wake cycle and its control
of periodic limb movements and REM sleep atonia.51,52
In the final stages of PD (ie, Braak stages 5 and 6), there is progression to the limbic
structures and cortex. The presence of cortical Lewy bodies has been suggested as a
primary cause of the cognitive dysfunction found in patients with PD in these stages of
disease.53 Also, decreased activity of choline acetyltransferase, the key synthetic
enzyme for acetylcholine production (which, in the PD brain, is at 40%–50% of normal
levels), has been noted, which also contributes to the cognitive dysfunction seen in pa-
tients with PD.45 The spread to the limbic system has been implicated in contributing
to mood disorders and psychosis.9
Complicating the deficiencies of other monoamines in the brains of patients with PD
is the use of levodopa, a precursor molecule that still remains the gold-standard phar-
macologic therapy. After passing through the blood-brain barrier, levodopa was theo-
rized to be taken up by surviving SN neurons and converted to dopamine by the
enzyme aromatic acid decarboxylase (AADC). However, the striking improvements
seen in motor functioning seemed unlikely if most dopamine neurons in the SN
were already degenerated.38,39 As a result, it has long been suspected that the effi-
cacy of levodopa in most patients with PD depends in part on surviving striatal
5-HT pathways originating from the raphe nuclei, which also contain AADC needed
for the synthesis of 5-HT. Because there was less degeneration in the raphe in patients
with PD compared with the SN, it was theorized that much of the conversion from
exogenous levodopa into dopamine happens in striatal 5-HT terminals. If this theory
is true, then it could further be deduced that increased amounts of exogenous levo-
dopa taken by patients with PD would overwhelm the AADC in raphe terminals,
causing them to begin producing dopamine at the expense of 5-HT. This hypothesis
has been supported by numerous in vivo experiments,54–59 implying that the use of
levodopa in patients with PD further exacerbates CNS 5-HT deficiency.
Another group of brainstem nuclei also containing AADC are NA-producing neurons
of the LC andmedullary reticular formation, which are also directly affected by PD.45–47
As a result, the use of levodopa may also influence NA utilization in these cells, with
potential clinical significance, which has rarely been acknowledged in the study of
this disease.60 For example, mounting evidence suggests that the LC provides direct
input to the SN and influences dopamine release in the striatum.60 In addition, the NA
produced in the LC influences activity in both the caudate and nucleus accumbens,
which are involved in numerous behaviors, such as the proclivity for addiction,61 and
may explain the impulse control disorders that can be seen with dopamine-
replacement therapy.33 In addition, evidence for abundant a2-noradrenergic receptors
of unknown significance have been documented in the striatum and cerebral cortex.62
Theoretically, these receptors may be involved with motor as well as nonmotor behav-
ioral functions, perhaps even playing a role in neuroprotection.60
NMS may also arise as a manifestation of pharmacotherapy. Treatment with dopa-
mine agonists has been linked to the development of impulse control disorders, and
treatment with levodopa can cause wearing off of NMS in addition to the more
commonly recognized wearing off of motor symptoms.8,37 This finding belies the
need for both a better understanding of the wearing-off phenomenon and of improved
treatments that cause neither the development nor fluctuations of NMS.
Although dopamine and nondopamine-producing nuclei and their influences on
motor symptoms and NMS have been discussed, these nuclei have complex
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pathophysiology of NMS is likely more multifactorial than based on single lesions.
Even although Braak staging41 does not provide an overall explanation for all NMS
and premotor findings, it is still helpful in understanding the pathogenesis of NMS
when combined with a broader view of PD as being more than merely a disorder of
dopamine deficiency in the brain. This is an important consideration when choosing
PD treatments for motor complaints and NMS, because therapies addressing beyond
just a striatal dopamine deficiency may be needed to treat PD in its entirety.ASSESSMENT OF NMS
Successful management of PD requires careful and early assessment and monitoring
that is specific for NMS, over and above the usual careful management of motor
symptoms.7,63 The importance of this requirement is highlighted by the recent Amer-
ican Academy of Neurology Parkinson’s Disease Quality Measures, in which half of the
questions specifically address NMS.64 However, although these measures state that
NMS should be recognized and managed, they do not provide direction on how this
should be accomplished.
Given the complexity of NMS, successful identification of these symptoms requires
a comprehensive approach. One common method is through the use of established,
validated questionnaires. Questionnaires that assess NMS range from those that
attempt to address aspects of individual symptoms to those that address the entire
NMS complex (see Table 2 for a summary). Although designed to augment routine
clinical assessment, questionnaires may be superior in some ways. It has been shown
that questionnaires may detect NMS undeclared during clinical assessment35 and
may be better at detecting wearing off of motor problems as well as NMS.65 Therefore,
use of such patient-administered questionnaires can be a useful clinical tool for NMS
assessment in the office setting.
The most commonly used patient-administered NMS questionnaire is the Non-
Motor Symptoms Questionnaire (NMS-Q),66 which was designed as a screening
tool. This 30-item questionnaire in yes/no format is used to determine whether or
not particular NMS are present and shows a sensitivity of 63.4% and specificity of
88.5% for all NMS.67 After the creation of the NMS-Q, a clinician-administered Non-
Motor Symptoms Scale (NMS-S) for PD was created to assess the frequency and
severity of these problems in patients with PD.68 The NMS-S is also 30 items in length,
but instead of simple yes/no responses, the clinician administering the questionnaire
is asked to rate the frequency and severity of each item. Frequency is rated from 1
(less than once per week) to 4 (daily or more often), and severity is rated from
0 (none) to 3 (severe). For each item, the frequency rating is multiplied by the severity
rating, and these values are summed to obtain the total NMS-S score. When
compared against other existing scales used in assessing PD, the NMS-S was found
to be free of floor or ceiling effects and to be valid and precise overall.69 Comparing the
NMS-Q with the NMS-S, the frequency of NMS reported varied between the 2 instru-
ments, with a higher correlation between patient and caregiver report using the
NMS-Q.13
In addition to the NMS-S and NMS-Q, there are broader questionnaires that assess
general quality of life as well as more specific questionnaires that may address 1
particular symptom. For example, quality-of-life questionnaires can be PD-specific,
such as in the Parkinson’s Disease Questionnaire (PDQ-39), or more general. A recent
task force assessed these quality-of-life questionnaires and reported that the PDQ-39
had the strongest significance and recommends its use in addition to other
Table 2
NMS questionnaires
NMS Addressed Scale Name Features Use
Entire NMS complex Non-Motor Symptoms
Questionnaire (NMS-Q)
30-item, self-completed
Yes/no responses
Screening for NMS
Non-Motor Symptoms
Scale (NMS-S)
30-item, clinician-administered
9 domains
Requires rating of frequency/severity of NMS
Quantitating NMS
PD quality of life Parkinson’s Disease
Questionnaire (PDQ-39)
39-item, clinician-administered
NMS only 1 aspect of PD covered by questionnaire
Assesses overall quality of life in PD
Autonomic dysfunction Scales for Outcomes in
Parkinson’s Disease
(SCOPA)–Autonomic
subscale
25-item, self-completed
Domains: gastrointestinal, urinary, cardiovascular,
thermoregulatory, pupillomotor, and sexual
dysfunction
Screens and measures severity of overall
autonomic problems
Cognitive dysfunction Parkinson’s Disease-Cognitive
Rating Scale (PD-CRS)
7 tasks, clinician-administered
More sensitive/specific for PD-related cognitive
problems than MMSE
Takes 15–30 min to administer
Screening for early PD-related cognitive
deficits and onset of PD dementia
SCOPA-Cognitive subscale 10 tasks, clinician-administered
More sensitive/specific for PD-related cognitive
problems than MMSE
Takes 10–15 min to administer
Screening for early PD-related
cognitive deficits
Depression Hamilton Depression
Index (Ham-D)
Has self-completed, clinician-administered, and
semistructured versions
17-item is most commonly used
Most widely used of all depression scales
Very high sensitivity/specificity
Screening and measuring severity
of depression
Beck Depression
Inventory (BDI)
21-item, self-completed, multiple choice responses
Moderate sensitivity/specificity
Most widely used self-completed depression scale
Screening and measuring severity
of depression
Montgomery-Asberg
Depression Rating
Scale (MADRS)
10-item, clinician-administered
Only 1 study in patients with PD
Very high sensitivity/specificity
Measuring change in severity of
depression, primarily for use in
studies; not designed for clinical
screening
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Sleep Parkinson’s Disease Sleep
Scale (PDSS)
15-item, self-completed, Likert scale
Designed for PD-related sleep problems
Looks at symptoms over the previous week
Screening and measuring severity
of overall sleep problems
SCOPA-Sleep subscale 12-item, self-completed
Looks at symptoms over the previous month
Screening and measuring severity
of overall sleep problems and
daytime sleepiness
Pittsburgh Sleep Quality
Index (PSQI)
19-item, self-completed
Looks at symptoms over the previous month
Screening and measuring severity
of overall sleep problems
Epworth Sleepiness
Scale (ESS)
8-item, self-completed
0–3 scoring for each item, cutoff of 10/11 for
pathologic sleepiness
Screening and measuring severity
of daytime sleepiness
Inappropriate Sleep Composite
Score (ISCS)
6-item, clinician-administered Screening and measuring of severe
daytime sleepiness or sleep attacks
Stanford Sleepiness Scale (SSS) 1-item, self-completed, yes/no responses Screening daytime sleepiness and
measuring severity at a specific
moment only
Apathy Apathy Evaluation Scale (AES) Likert scale with 18 items; 4 items scored by patient
alone, 1 item by rater alone
Screening for apathy in treatment
studies
Apathy Scale (AS) – Modified Abridged AES developed for PD
4-point Likert scale with 14 items, scored by patient
(items are read to patient)
Screening for apathy in treatment
studies
Lille Apathy Rating Scale
(LARS)
33-item, structured interview with yes/no or Likert
scale responses
Screening for apathy in treatment
studies
Anhedonia Snaith-Hamilton Pleasure Scale 14-item, self-completed, Likert scales Screening for anhedonia in treatment
studies
Abbreviation: MMSE, Mini-Mental State Examination.
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Sung & NicholasS10disease-specific instruments (Parkinson’s Disease Questionnaire Short Form, Parkin-
son’s Disease Quality of Life Questionnaire, Parkinson’s Impact Scale, and Scales for
Outcomes in Parkinson’s Disease-Psychosocial) and general questionnaires
(EuroQoL-5, Nottingham Health Profile, 36-Item Short-Form Health Survey, and Sick-
ness Impact Profile).70 Another commonly used tool is the Scales for Outcomes in
Parkinson’s Disease (SCOPA), which has multiple subscales, including measurement
of motor, cognitive, sleep, autonomic, and psychiatric complications (SCOPA-PC).71
The SCOPA provides outcome measures for both motor problems and NMS and, in
several recent reviews, the different SCOPA subscales have been compared with
various other symptom-specific scales.72–75
For the NMS of sleep dysfunction, a review by Hogl and colleagues73 recommends
the Parkinson’s Disease Sleep Scale (PDSS), SCOPA-sleep, and the Pittsburgh Sleep
Quality Index for both screening and measuring severity of overall sleep problems. For
scales to screen andmeasure daytime sleepiness, the same investigators recommend
the Epworth Sleepiness Scale (ESS), whereas the Inappropriate Sleep Composite
Score and the Stanford Sleepiness Scale were suggested only for use as alternatives
to the ESS.73
For the NMS of dysautonomia, Evatt and colleagues72 recommends the SCOPA-
Autonomic and NMS-Q, based on the specific use of these instruments in PD clinical
studies, which was beyond the group that developed it, thereby verifying its validity,
reliability, and sensitivity.
For the NMS of cognitive dysfunction, the Parkinson’s Disease–Cognitive Rating
Scale (PD-CRS) and the SCOPA-Cognitive subscale were most recommended, ac-
cording to Kulisevsky and Pagonabarraga,74 because of their strongest validation
scores. Both tools were designed specifically to detect cognitive deficits in patients
with PD, as opposed to other forms of dementia, and both were deemed superior
to the more commonly used Mini-Mental State Examination (MMSE) in sensitivity for
PD-related cognitive dysfunction. The MMSE has never been validated in populations
with PD.
For the NMS of depression, the Beck Depression Inventory (BDI), Hamilton Depres-
sion Scale (Ham-D), and Montgomery-Asberg Depression Rating Scale (MADRS)
were found to be the most useful scales for both screening and measurement of
severity of depression related to PD.75 The MADRS was not designed for clinical
screening, although it was applied as such in 1 study in patients with PD. The BDI
and Ham-D have both been used extensively in patients with PD. The BDI is
completed by the patient, whereas the Ham-D has both clinician-administered and
patient-completed components. Apathy and anhedonia are related to depression,
which can also be signs of depression in patients with PD but can also be separately
related to PD itself. Although there are scales that have been developed for apathy
(Apathy Evaluation Scale, Lille Apathy Rating Scale) and anhedonia (Snaith-Hamilton
Pleasure Scale), their use has been primarily limited to treatment studies and not to
clinical screening.
In addition to screening for the presence of NMS, many of these questionnaires also
measure severity of NMS complaints, providing a helpful tool for the clinician to help
guide treatment. However, other efforts are still needed to raise awareness about the
meaning of NMS in the cause and progression of PD. As alluded to previously, NMS
are being evaluated as potential core features of the premotor stage of PD,76 which
has significant implications in predicting the manifestation of motor problems in PD,
as well as defining an at-risk population for developing PD. NMS may also have value
as biomarkers for the progression of PD, because the number of NMS reported by pa-
tients correlate significantly with advancing disease.5
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Of existing treatments, several options may be considered for management of NMS.
Table 3 summarizes conclusions of the 2010 American Academy of Neurology (AAN)
Practice Parameters for NMS in PD11 and the Movement Disorder Society (MDS) rec-
ommendations for treatment of NMS from 2011,77 as well as a clinical review by Wood
and colleagues78 from 2010. The AAN and MDS recommendations applied rigorous
criteria and only recommend therapies that have shown robust evidence-based sup-
port for their use, whereas the Wood and colleagues review evaluated expert opinions
in addition to clinical studies and provides clinically based recommendations.
For constipation, all 3 groups agree that evidence supports the use of isosmotic
macrogol (polyethylene glycol).11,77,78 Wood and colleagues78 also note that, when
treating GI dysfunction in patients with PD, the practitioner must take special careTable 3
Summary of evidence-based treatment guidelines for NMS in PD
NMS
American Academy of
Neurology Practice
Parameter
Movement Disorder
Society
Recommendations
Clinical Review
Recommendations
Constipation Polyethylene glycol Polyethylene glycol Polyethylene glycol;
avoid dopamine-
blocking
antiemetics
Orthostatic
hypotension
Insufficient evidence Insufficient evidence Begin with
nonpharmacologic
interventions
(increased fluid/salt
intake, compressive
stockings)
If fails, add
fludrocortisone
and/or midodrine
Depression Insufficient evidence Evidence supports use
of nortriptyline,
desipramine, and
pramipexole; avoid
nefazodone
Although no
evidence, expert
opinion favors use
of selective
serotonin reuptake
inhibitors as first-
line treatment
Psychosis Reduce dopaminergic
medication where
possible
Reduce dopaminergic
medication where
possible
Evidence supports use
of clozapine; avoid
olanzapine
Reduce dopaminergic
medication where
possible
Quetiapine or, if
ineffective,
clozapine
Dementia Not mentioned Rivastigmine All cholinesterase
inhibitors
Sleep-related
dysfunction
Consider modafinil for
excessive daytime
somnolence
Consider
methylphenidate
for fatigue
No mention Tailor treatment to
individual patient’s
predominant
symptoms
Sung & NicholasS12to avoid antiemetics with dopamine receptor-blocking properties (eg, metoclopra-
mide, prochlorperazine).
For autonomic dysfunction manifested as orthostasis, the most common treatment
plan is to begin with nonpharmacologic interventions such as increased fluid/salt
intake and compressive stockings, followed by pharmacologic treatments such as flu-
drocortisone, midodrine, or indomethacin. Both the AAN and MDS reviews state that
there is insufficient evidence to strongly support or refute these treatments.11,77
Regarding mood disorders in PD, expert opinion favors the use of selective seroto-
nin reuptake inhibitors as first-line therapy, although all 3 reviews report that there is
little evidence to support this. For depression, the strongest evidence supports the
use of nortriptyline, desipramine, and pramipexole.77 In addition, the MDS review
states that nefazodone should be avoided for safety reasons.77 For psychosis occur-
ring in patients with PD, the general recommendation is to start by reducing dopamine
therapy for motor symptoms, when possible.78 If this strategy fails, then there is, in
general, common use of quetiapine or clozapine.78 However, although there is good
evidence to support the use of clozapine,77 there is still insufficient evidence to recom-
mend the use of quetiapine.11,77 The MDS review makes specific mention that olanza-
pine should be avoided because of safety concerns.77
For cognitive abnormalities, specifically dementia occurring in PD, the strongest
evidence supports the use of rivastigmine77; however, there is wide use of all of the
central cholinesterase inhibitors.78
Regarding sleep-related dysfunction, Wood and colleagues78 noted that, from
insomnia to daytime hypersomnolence to REM sleep behavioral disorder to restless
legs syndrome, sleep disorders of PD can vary among individual patients; therefore,
therapies should be tailored for each patient’s most prominent symptoms. The AAN
review recommends consideration of modafinil in the treatment of EDS and methyl-
phenidate in the treatment of fatigue in patients with PD.11 The MDS review also
reported that there are several ongoing randomized controlled trials; therefore, the
data need to be continuously monitored so that recommendations for treatment
remain up to date. Overall, all 3 reviews11,77,78 agree that there is still much work to
be done to improve evidence-based treatment of NMS in PD and many more clinical
data are needed to develop more robust treatment guidelines for NMS.SUMMARY
The pathology of PD extends beyond the nigrostriatal dopamine pathway and results
in NMS in addition to the commonly accepted motor symptoms. NMS have a great
impact on quality of life, but nonrecognition of NMS is an all too common problem,
requiring a systematic approach to both recognizing and treating NMS. There are
many useful questionnaires that might be used to detect and guide management of
NMS. However, as reported here, the number of evidence-based treatments for these
problems remains limited. Most work needs to be done in therapeutics, and it seems
that future therapies for NMS should be developed specifically based on the patho-
genesis of PD. Therapeutic strategies that use 5-HT-based and NA-based ap-
proaches, in addition to dopamine therapy, may provide a more comprehensive
control of the multitude of symptoms seen in most patients with PD.REFERENCES
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